Breast Cancer Trial of RPR109881 Versus Capecitabine in Male or Female Patients With Advanced Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Metastases
Interventions: DRUG: larotaxel (RPR109881, XRP9881)|DRUG: capecitabine
Sponsor: Sanofi